NEW YORK (GenomeWeb News) – Harvard Medical School researchers will use High Throughput Genomics’ technology to develop an assay that can measure the expression of miRNA precursors, mature microRNAs, and regulated RNA.
Tucson, Ariz.-based HTG said today that it will collaborate with the Harvard Catalyst Laboratory for Innovative Translational Technologies at Harvard Medical School to create the biogenesis assay.
Under the agreement, the lab will use HTG’s quantitative Nuclease Protection Assay technology, which the company said allows researchers to “test any sample, including fixed tissues, without RNA extraction or target amplification.” The qNPA technology is used to carry out quantitative, multiplexed gene-based drug programs, including target validation, HTS lead optimization, metabolism, toxicology, and clinical development.
Financial terms of the agreement were not released.